Brought to you by 
Sage Therapeutics nets $561mm in FOPO
12 Mar 2019
Executive Summary
Sage Therapeutics Inc. (focused on selective allosteric GABAA modulation) netted $561.3mm through the public offering of 3.8mm shares (including the overallotment) at $150. Sage will put the proceeds toward the US commercial launch of Zulresso (SAGE547; brexanolone) for postpartum depression, if approved (an NDA was filed in 2018 with an extended PDUFA date of March 19, 2019); ongoing development of and initial pre-commercial activities for SAGE217 in major depressive disorder (Phase III), bipolar depression (Phase II), and insomnia (Phase I); and advancement of Phase I candidates SAGE324 (essential tremor and epileptiform disorders) and SAGE718 (cognition-related disorders, including Huntington’s disease).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sage Therapeutics nets $561mm in FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice